ClinicalTrials.gg
CompletedNCT07684196Updated Nov 13, 2026

A First-in-Human SAD/MAD Study to Evaluate Safety, Tolerability and PK of ENC0653 Ointment in Healthy Adult Subjects

A Phase 1 interventional study of Low Dose, 10%BSA and Low Dose, 20%BSA in Healthy, sponsored by EnnovaBio. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by EnnovaBio · Phase 1, Interventional, and Treatment

How we know

Updated Nov 13, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a FIH, randomized, double-blind, single-center, placebo-controlled, dose -escalation clinical study to evaluate the safety, tolerability and pharmacokinetics of ENC0653 ointment following single and multiple topical dermal administration in healthy adult subjects.

Up to 56 subjects will be enrolled at a single site in up to 4 cohorts in Part A (SAD study), and up to 3 cohorts in Part B (MAD study). Part A is for the single dose use of IP, while Part B is twice-daily use for 7 consecutive days and once daily use on Day 8. Each cohort will include 8 subjects (6 receiving ENC0653 ointment and 2 receiving placebo ointment).

Dosing will be escalated on a review of safety, tolerability, and available PK data by a Safety Review Committee (SRC).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

EnnovaBio is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject signs the form (ICF) prior to enrollment after full disclosure of study procedures and requirements. The subject understands the necessity of following study rules and completing all assessments on time, is fully informed of study procedures, and potential adverse reactions, and is able to complete the study in accordance with the protocol requirements.
  • Aged ≥ 18 years and ≤ 55 years on the date of signing the informed consent form, male or female.
  • Male subjects with body weight ≥ 50 kg, female subjects with body weight ≥ 45 kg, and (BMI) within the range of 18.0-32.0 kg/m² (inclusive).
  • No ulceration, injury, sunburn, erythema, rash, or abnormal warmth, as well as tattoos, birthmarks, skin scars, or skin perforations shall be present on the target application regions at screening and prior to dosing.
  • The subject gives voluntary consent to employ adequate methods from 2 weeks prior to dosing until 1 month after the last study visit, and to refrain from sperm or egg donation during this period.

Exclusion criteria

Exclusion Criteria:

  • The subject has any skin disorders deemed by the investigator to be a study or to compromise assessment of the application region, including psoriasis, eczema, acne, atopic dermatitis, dysplastic nevi, other dermatologic lesions, or a history of cutaneous .
  • Presence of any of the following high-risk conditions: history of deep vein thrombosis, arterial thrombosis, or pulmonary embolism; family history of thromboembolism (e.g., myocardial infarction or cerebral infarction in family members); history of malignancy; serious organ or systemic disease, immune-mediated disease (including but not limited to rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, psoriatic arthritis, etc.), or any diseases deemed by the investigator to render the subject unsuitable for enrollment in this study.
  • Presence of any active cutaneous infections of acute bacterial, fungal, or viral (e.g., herpes simplex, herpes zoster, varicella, etc.) within 1 week prior to signing the ICF; or any acute or chronic infections requiring systemic treatment with antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks prior to signing the ICF.
  • History of severe trauma or major surgery within 3 months prior to screening; plan to receive surgery during the trial or within 2 weeks after completion of the trial.
  • History of active tuberculosis, or clinical symptoms/signs or chest X-ray findings suggestive of active tuberculosis.
  • Positive test results for surface antigen (HBsAg), virus antibody (HCV-Ab), (HIV) antibody, or Treponema pallidum antibody (TP-Ab).
  • Pregnant, breast-feeding and/or lactating women.
  • , AST or TBiL ≥1.5ULN
  • Has received any within 1 month prior to screening or intend to receive a live vaccine during the study period or within 30 days after the last dose.
  • The subject who has participated in any clinical trial of drugs or medical devices within 3 months prior to screening (or 5 half-lives, whichever is longer).
  • Other factors considered inappropriate for inclusion in this study at the discretion of the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose, Low Dose, 10%BSA

    Topical dermal administration

    Drug: Low Dose, 10%BSA

  • Experimental
    Single Ascending Dose, Low Dose, 20%BSA

    Topical dermal administration

    Drug: Low Dose, 20%BSA

  • Experimental
    Single Ascending Dose, Middle Dose, 20%BSA

    Topical dermal administration

    Drug: Middle Dose, 20%BSA

  • Experimental
    Single Ascending Dose, High Dose, 20%BSA

    Topical dermal administration

    Drug: High Dose, 20%BSA

  • Experimental
    Multiple Ascending Dose, Low Dose, 20%BSA

    Topical dermal administration

    Drug: Low Dose, 20%BSA

  • Experimental
    Multiple Ascending Dose, Middle Dose, 20%BSA

    Topical dermal administration

    Drug: Middle Dose, 20%BSA

  • Experimental
    Multiple Ascending Dose, High Dose, 20%BSA

    Topical dermal administration

    Drug: High Dose, 20%BSA

  • Placebo comparator
    Single/Multiple Ascending Dose, Placebo Ointment

    Placebo ointment for topical dermal administration

    Drug: Placebo

Interventions

  • DrugLow Dose, 10%BSA

    Topical dermal administration

  • DrugLow Dose, 20%BSA

    Topical dermal administration

  • DrugMiddle Dose, 20%BSA

    Topical dermal administration

  • DrugHigh Dose, 20%BSA

    Topical dermal administration

  • DrugLow Dose, 20%BSA

    Topical dermal administration

  • DrugMiddle Dose, 20%BSA

    Topical dermal administration

  • DrugHigh Dose, 20%BSA

    Topical dermal administration

  • DrugPlacebo

    Topical dermal administration

06

What researchers measure

Primary outcomes

  1. Number and types of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) following ENC0653 ointment administration

    Time frame: D-28 to Day 4 (± 1) for SAD and D-28 to Day 11 (± 1) for MAD

Secondary outcomes

  1. Plasma drug concentrations

    Time frame: Single Ascending Dose (SAD) part: up to Day 4, 72 hours post dose; Multiple Ascending Dose (MAD) part: up to Day 11, 72 hours post last dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2026 to primary completion in Oct 2026, 4 months.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jul 6, 2026
StartActual
Jun 22, 2026
Primary completionActual
Oct 27, 2026
CompletionActual
Oct 27, 2026was Dec 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 13, 2026
Start date
Jun 17, 2026→Jun 22, 2026 (actual)
Nov 13, 2026
Primary completion
Oct 1, 2026→Oct 27, 2026 (actual)
Nov 13, 2026
Study completion
Dec 30, 2026→Oct 27, 2026 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Completed
    Start date Jun 17, 2026→Jun 22, 2026 (now actual)
    Primary completion Oct 1, 2026→Oct 27, 2026 (now actual)
    Study completion Dec 30, 2026→Oct 27, 2026 (now actual)
    + 2 other changes: site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07684196
Lead sponsor
EnnovaBio
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Jun 22, 2026
Primary completion
Oct 27, 2026
Completion
Oct 27, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion